Par Fights FDA Forfeiture Of Generic Colcrys Exclusivity
Executive Summary
Pursing legal action against the agency in an area where it is sometimes vulnerable, Par argues that amending its proposed label did not interrupt paragraph IV certification for the firm's colchicine ANDA.
You may also be interested in...
US FDA Gives Directions On Navigating Generic 180-Day Exclusivity Maze
Draft guidance sums up agency’s policies for determining exclusivity, clarifies when the clock starts for failure to market.
US FDA Gives Directions On Navigating Generic 180-Day Exclusivity Maze
Draft guidance sums up agency’s policies for determining exclusivity, clarifies when the clock starts for failure to market.
FDA New Year’s Resolution: Guidances On Payor Communications, Biosimilarity
Agency expects to issue 101 guidances in 2017, including those on REMS assessment, refusal to file NDA and BLA submissions, and amendments to ANDAs.